서울대학교 중앙도서관
S-Space 소개
My S-Space
로그인이 필요합니다.
Login

S-Space

Browse

Publisher

Jump to a point in the index
Or type in a year

  • Sort by
  • In order
  • Results/Page
  • Authors/record

Showing results 1 to 40 of 58

Issue DateTitle / Author(s) / CitationFileAltmetrics
2009-11
Differences in the Expression Profiles of Excision Repair Crosscomplementation Group 1, X-Ray Repair Crosscomplementation Group 1, and beta III-Tubulin Between Primary Non-small Cell Lung Cancer and Metastatic Lymph Nodes and the Significance in Mid-Term Survival
DOI
2010-02
Timing of local and distant failure in resected lung cancer: Implications for reported rates of local failure

Boyd, Jessamy A.; Hubbs, Jessica L.; Kim, Dong W.; Hollis, Donna; Marks, Lawrence B.; Kelsey, Chris R.

Journal of Thoracic Oncology, Vol.5 No.2, pp.211-214

DOI
2010-03
Expression of Class III Beta-Tubulin Correlates with Unfavorable Survival Outcome in Patients with Resected Non-small Cell Lung Cancer
DOI
2010-12
Rapid and Dramatic Radiographic and Clinical Response to an ALK Inhibitor (Crizotinib, PF02341066) in an ALK Translocation-Positive Patient with Non-small Cell Lung Cancer
DOI
2011-03
Screening of anaplastic lymphoma kinase rearrangement by immunohistochemistry in non-small cell lung cancer: Correlation with fluorescence in situ hybridization
DOI
2011-05
Clinicopathologic Characteristics and Outcomes of Patients with Anaplastic Lymphoma Kinase-Positive Advanced Pulmonary Adenocarcinoma Suggestion for an Effective Screening Strategy for These Tumors
DOI
2011-05
Activity of Crizotinib (PF02341066), a Dual Mesenchymal-Epithelial Transition (MET) and Anaplastic Lymphoma Kinase (ALK) Inhibitor, in a Non-small Cell Lung Cancer Patient with De Novo MET Amplification
DOI
2011-08
Detection of ALK gene rearrangement in non-small cell lung cancer: A comparison of fluorescence in situ hybridization and chromogenic in situ hybridization with correlation of ALK protein expression
DOI
2011-09
Anaplastic Lymphoma Kinase Translocation A Predictive Biomarker of Pemetrexed in Patients with Non-small Cell Lung Cancer
DOI
2013-04
Heterogeneity of Genetic Changes Associated with Acquired Crizotinib Resistance in ALK-Rearranged Lung Cancer
DOI
2013-07
Postoperative occipital neuralgia with and without C2 nerve root transection during atlantoaxial screw fixation: a post-hoc comparative outcome study of prospectively collected data
view fileDOI
2013-07
Risk of vertebral artery injury: comparison between C1-C2 transarticular and C2 pedicle screws.
view fileDOI
2013-08
Erlotinib Versus Gefitinib for Control of Leptomeningeal Carcinomatosis in Non-Small-Cell Lung Cancer

Lee, Eunyoung; Keam, Bhumsuk; Kim, Dong-Wan; Kim, Tae Min; Lee, Se-Hoon; Chung, Doo Hyun; Heo, Dae Seog

Journal of Thoracic Oncology, Vol.8 No.8, pp.1069-1074

DOI
2013-11
Clinicopathologic Analysis of ROS1-Rearranged Non-Small-Cell Lung Cancer and Proposal of a Diagnostic Algorithm
DOI
2014-10
Safety and Efficacy of Dacomitinib in Korean Patients with KRAS Wild-Type Advanced Non-Small-Cell Lung Cancer Refractory to Chemotherapy and Erlotinib or Gefitinib A Phase I/II Trial
DOI
2014-11
Patient-Reported Outcomes and Quality of Life in PROFILE 1007: A Randomized Trial of Crizotinib Compared with Chemotherapy in Previously Treated Patients with ALK-Positive Advanced Non-Small-Cell Lung Cancer
DOI
2015-05
THE EFFICACY OF ONCE-DAILY ADMINISTRATION OF UDENAFIL FOR 24 WEEKS ON ERECTILE DYSFUNCTION AND LOWER URINARY TRACT SYMPTOMS; RESULTS FROM A RANDOMIZED MULTICENTER PLACEBO-CONTROLLED CLINICAL TRIAL
2015-08
Total lesion glycolysis in positron emission tomography can predict gefitinib outcomes in non-small-cell lung cancer with activating EGFR mutation
DOI
2015-12
Mechanisms of Acquired Resistance to AZD9291 A Mutation-Selective, Irreversible EGFR Inhibitor
DOI
2017-02
Allogeneic hair transplantation with enhanced survival by anti-ICAM-1 antibody with short-term rapamycin treatment in nonhuman primates
DOI
2017-03
Prognostic Impact of Newly Proposed M Descriptors in TNM Classification of Non-Small Cell Lung Cancer
DOI
2017-08
Scientific Advances in Thoracic Oncology 2016
DOI
2017-09
ASCEND-8: A randomized phase 1 study of ceritinib, 450 mg or 600 mg, taken with a low-fat meal versus 750 mg in fasted state in patients with anaplastic lymphoma kinase (ALK)-rearranged metastatic non-small cell lung cancer (NSCLC)
DOI
2017-10
Pooled systemic efficacy and safety data from the pivotal phase II studies (NP28673 and NP28761) of alectinib in ALK-positive non-small cell lung cancer
DOI
2018-02
Interobserver variation among pathologists and refinement of criteria in distinguishing separate primary tumors from intrapulmonary metastases in lung
DOI
2018-04
Phase 2 study of the HSP-90 inhibitor AUY922 in previously treated and molecularly defined patients with advanced non-small cell lung cancer
DOI
2019-05
Health-Related Quality of Life in KEYNOTE-010: a Phase II/III Study of Pembrolizumab Versus Docetaxel in Patients With Previously Treated Advanced, Programmed Death Ligand 1-Expressing NSCLC
DOI
2019-05
Osimertinib Plus Durvalumab versus Osimertinib Monotherapy in EGFR T790M-Positive NSCLC following Previous EGFR TKI Therapy: CAURAL Brief Report
DOI
2019-07
Advanced-Stage Non–Small Cell Lung Cancer: Advances in Thoracic Oncology 2018
DOI
2019-09
Preclinical Modeling of Osimertinib for NSCLC With EGFR Exon 20 Insertion Mutations

Lee, Yusoo; Kim, Tae Min; Kim, Dong-Wan; Kim, Soyeon; Kim, Miso; Keam, Bhumsuk; Ku, Ja-Lok; Heo, Dae Seog

Journal of Thoracic Oncology, Vol.14 No.9, pp.1556-1566

DOI
2019-10
Corrigendum to Effects of 17β-estradiol on colorectal cancer development after azoxymethane/dextran sulfate sodium treatment of ovariectomized mice (Biochemical Pharmacology (2019) 164 (139–151), (S0006295219301467), (10.1016/j.bcp.2019.04.011))
DOI
2019-10
Clinical Activity, Tolerability, and Long-Term Follow-Up of Durvalumab in Patients With Advanced NSCLC
DOI
2020-03
Asian Thoracic Oncology Research Group Expert Consensus Statement on Optimal Management of Stage III NSCLC
DOI
2020-03
Brigatinib in Crizotinib-Refractory ALK+ NSCLC: 2-Year Follow-up on Systemic and Intracranial Outcomes in the Phase 2 ALTA Trial
DOI
2020-04
Pembrolizumab After Two or More Lines of Previous Therapy in Patients With Recurrent or Metastatic SCLC: Results From the KEYNOTE-028 and KEYNOTE-158 Studies
DOI
2020-05
Kidney residency of VISTA -positive macrophages accelerates repair from ischemic injury
DOI
2020-09
Chloronychia caused by Pseudomonas oryzihabitans infection

Hur, Keunyoung; Cho, Soyun

JAAD Case Reports, Vol.6 No.9, pp.918-920

DOI
2020-09
An International Real-World Analysis of the Efficacy and Safety of Lorlatinib Through Early or Expanded Access Programs in Patients With Tyrosine Kinase Inhibitor-Refractory ALK-Positive or ROS1-Positive NSCLC
DOI
2021-01
Durability of Clinical Benefit and Biomarkers in Patients with Advanced Non-Small Cell Lung Cancer (NSCLC) Treated with Sotorasib, a KRAS(G12C) Inhibitor
DOI
2021-02
Outcomes According to ALK Status Determined by Central Immunohistochemistry or Fluorescence In Situ Hybridization in Patients With ALK-Positive NSCLC Enrolled in the Phase 3 ALEX Study
DOI
1 2